Home Compare BMY vs GSK.L
Stock Comparison · Industry comparison · Drug Manufacturers - General

Bristol-Myers Squibb Company vs GSK: Which Stock Looks Stronger in 2026?

The structural profiles are close, with GSK carrying a narrow edge on stability. The remaining gap is narrow enough that the comparison remains open to different readings. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The overall separation remains limited, with no one area creating a decisive distance.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BMY and GSK.L share the same industry classification.

For a similarity-based comparison, see how BMY and GSK each position within their functional peer groups in AssetNext.

Peer-Relative Score
BMY
Bristol-Myers Squibb Company
61
Peer-Score
Signal qualityHigh
vs
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: BMY vs GSK.L Profitability 38 46 Stability 56 69 Valuation 86 80 Growth 62 71 BMY GSK.L
Gap Ranking
#1 Stability +13
#2 Growth +9
#3 Profitability +8
#4 Valuation +6
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BMY and GSK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BMYGSK.L Relative valuation Structural strength

GSK plc occupies the cheaper side of the setup map, although Bristol-Myers Squibb Company still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
Both rank well on stability, but GSK plc still sits higher.
Growth
On growth, the same pattern holds: both rank well, but GSK plc still sits higher.
Stability — Dominant Gap
BMY
56
GSK.L
69
Gap+13in favour of GSK.L

The clearest distance comes from a steadier profile over time.

What keeps the gap from being one-sided

Bristol-Myers Squibb Company still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The structural lead holds, but pricing still pulls in a different direction — keeping the result from looking fully aligned.

Explore full peer positioning in AssetNext

Break down the BMY vs GSK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other close comparisons

Explore how BMY and GSK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.